Transgene (XPAR:TNG) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


XPAR:TNG Transgene SA XPAR:TNG
44 GF Score
Price €0.73
GF Value €0.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Transgene Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Transgene's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XPAR:TNG vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Transgene's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Transgene's Margin of Safety % (DCF Earnings Based) falls into.


XPAR:TNG
44GF Score
Transgene SA XPAR:TNG
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Transgene (XPAR:TNG) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene stock appears to be overvalued. The current stock price of €0.73 is trading 37.9% above its estimated GF Value™ of €0.53. GuruFocus considers Transgene to be Significantly Overvalued.

Key valuation signals for XPAR:TNG:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.53 vs. price of €0.73 (37.9% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the XPAR:TNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Business Description

Address 400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
44GF Score

Get the complete analysis for XPAR:TNG

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.73
Price
€0.53
GF Value